英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
symptomize查看　symptomize　在百度字典中的解释百度英翻中〔查看〕
symptomize查看　symptomize　在Google字典中的解释Google英翻中〔查看〕
symptomize查看　symptomize　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Advanced and metastatic prostate cancer: ESMO Clinical . . .
    This includes metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) The management of early-stage disease is covered in the ESMO CPG for local and locoregional prostate cancer 1
  • Niraparib and abiraterone acetate plus prednisone for HRR . . .
    We hypothesized that PARP inhibition within 6 months of starting androgen deprivation therapy for metastatic castration-sensitive prostate cancer (mCSPC) could be effective and improve
  • Advanced Prostate Cancer Update: Adding PARP Inhibitor To . . .
    Patients with metastatic castration-sensitive prostate cancer (mCSPC), who have specific genetic mutations, were found to have improved survival by using a targeted treatment called PARP inhibitors combined with standard therapy with an androgen receptor (AR) pathway inhibitor The findings came
  • Metastatic Castration-Sensitive Prostate Cancer: Optimizing . . .
    Further incremental progress in the outcome of patients with mCSPC came from the addition of novel agents, docetaxel or abiraterone, to ADT for more aggressive up-front treatment of metastatic prostate cancer
  • Efficacy and safety of treatments for metastatic castration . . .
    Metastatic prostate cancer that has not previously been treated with ADT is considered to be castration-sensitive prostate cancer (mCSPC)
  • Advanced and metastatic prostate cancer: ESMO Clinical . . .
    This includes metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) The management of early-stage disease is covered in the ESMO CPG for local and locoregional prostate cancer 1
  • Prostate Cancer, Version 3. 2026 - jnccn. org
    Abstract The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions for patients with prostate cancer across the dis-ease spectrum The Guidelines sections included in this article focus on metastatic castration-sensitive prostate cancer (mCSPC), nonmeta-static castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC) For patients with mCSPC, disease
  • Prostate Cancer, Version 3. 2026, NCCN Clinical Practice . . .
    The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions for patients with prostate cancer across the disease spectrum The Guidelines sections included in this article focus on metastatic castration-sensitive prostate cancer (mCSPC), nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC) For patients with mCSPC, disease
  • Packing the Punch: Current and Emerging Treatment Strategies . . .
    Purpose of Review Prostate cancer remains a significant source of morbidity and mortality worldwide, with metastatic castration-sensitive disease (mCSPC) representing a complex therapeutic challenge This review explores how a deeper understanding of the androgen receptor axis has shifted mCSPC management from monotherapy to more intense treatment We discuss emerging data on triplet regimens
  • Real-world treatment patterns and outcomes in advanced . . .
    Time burden and healthcare costs associated with docetaxel in patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating an androgen receptor pathway inhibitor (ARPI) –based regimen This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium This





中文字典-英文字典  2005-2009